Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors

Abstract Background Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) shows substantial antitumor efficacy. Here, we report the preclinical data and outcomes of a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in advanced solid tumors. Methods In preclinical studie...

Full description

Bibliographic Details

Published in:	Experimental Hematology & Oncology
Main Authors:	Chenfei Zhou, Jinling Jiang, Xiaojun Xiang, Hongli Liu, Guowu Wu, Ruichao Zeng, Tong Lu, Mengqi Zhang, Yuteng Shen, Min Hong, Jun Zhang
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	CTLA-4 JS007 Monoclonal antibody Solid tumors Immunotherapy
Online Access:	https://doi.org/10.1186/s40164-024-00567-7